Columbia University College of Physicians and Surgeons, USA View all
Journal of Liver: Disease & Transplantation (JLDT) is a peer-reviewed online journal and aims to publish the most complete and reliable source of information on the discoveries and current developments in the mode of original articles, review articles, case reports, short communications, etc. in all areas of liver pathology and making them available to researchers worldwide.
Journal of Liver: Disease & Transplantation focuses on the topics hepatitis, cirrhosis, liver cancer, alcohol damage, fatty liver, metabolic and genetic liver diseases, autoimmune liver diseases, liver transplantation and techniques, surgical complications and transplantation outcomes.
The Journal is using Editorial Manager System for quality in review process. Editorial Manager is an online manuscript submission, review and tracking systems. Review processing is performed by the editorial board members of Journal of Liver: Disease & Transplantationor outside experts; at least two independent reviewers approval followed by editor approval is required for acceptance of any citable manuscript. Authors may submit manuscripts and track their progress through the system, hopefully to publication. Reviewers can download manuscripts and submit their opinions to the editor. Editors can manage the whole submission/review/revise/publish process.
CD47, A Potential Therapeutic Target for Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is among the most frequent cancers in the world; ranking in fifth most commonly diagnosed cancer and is one of the leading causes of cancer death. HCC is often diagnosed in advanced stages where prognosis is poor and tumors are often inoperable. At an advanced stage, the response to chemotherapeutic drugs is unsatisfactory and shows high recurrence rates even if surgically resected. The limited treatment options for patients with advanced HCC encourage the elucidation of the pathogenesis pathway involved to identify potential therapeutic targets to improve the treatment for HCC. Recent research shows increasing evidence of upregulation of CD47, an integrin-associated transmembrane protein, in numerous human tumors including HCC, allowing it to serve as a cancer cell marker.
Hepatic Glycogenosis in a Patient with Type 1 Myotonic Dystrophy
Myotonic dystrophy is an autosomal dominant, inherited disorder, characterized by progressive distal muscle weakness and impaired muscle relaxation. DM1 patients may present with elevated transaminases that are typically related to metabolic syndrome and non-alcoholic fatty liver disease. We report a patient whose diagnosis of DM1 was established after an initial referral for abnormal transaminases. On liver biopsy, the patient was found to have no evidence of NASH, but abnormal glycogen deposits in hepatocytes. The potential link between hepatocyte glycogen storage and DM1 remains to be further explored.
Surgical Emergencies in Liver Hydatidosis: Not too Much, but Severe
Liver hydatidosis is a zoonosis caused by Echinococcus that has worldwide distribution. There are three types of therapeutical options: surgery, medical treatment and PAIR. But surgery is the treatment that offers better long-term results. Usually surgery for liver hydatidosis is made as a scheduled procedure, but sometimes, severe symptoms provoked by liver cysts must be treated in emergency setting. We have made a review of every complication that could provoke liver hydatidosis: complications related to cysto-biliary communication, intraperitoneal rupture, vascular complications and rupture in surrounding organs. We have made a review of epidemiology, diagnosis and treatment of each complication, focusing when an emergency treatment is needed. We could conclude that only few patients require an emergency treatment due to liver hydatidosis, but morbidity and even mortality is high because diagnosis is difficult and sometimes delayed, and we have to face to severe medical situations.
Scientific Publications Regarding Liver Cirrhosis and Portal Hypertension in 6 Science Citation Index Hepatology Specialized Journals from 2009 To 2011
We analyzed the original papers regarding liver cirrhosis and portal hypertension in 6 science citation index journals that are specialized in hepatology (i.e., Hepatology, Journal of Hepatology, Liver International, Hepatology International, Hepatology Research, and Annals of Hepatology). Methods: All original papers published in these journals between 2009 and 2011 were identified. The proportion of original papers regarding cirrhosis and portal hypertension was calculated, and was compared among different journals. Other characteristics of these papers were also reported.Conclusions: A low proportion of original papers regarding cirrhosis and portal hypertension suggested that more high-quality researches should be performed.
Complete Resolution of a Malignant Biliary Stricture Using Combined Neoadjuvant Chemoradiation and Brachytherapy Boost Prior to Orthotopic Liver Transplantation
To limit recurrence and intra-operative tumor dissemination at the time of transplant, there is increasing evidence that neoadjuvant chemoradiation and brachytherapy boost helps facilitate successful liver transplantation in patients with earlystage unresectable hilar cholangiocarcinoma. In published reports, a complete response to neoadjuvant therapy frequently limits the ability to detect residual disease in the hepatectomy specimen, thereby inviting criticism over whether published results are due to the neoadjuvant protocol per se, or selection of patients with earlystage or pre-malignant disease. In this report, a 41 year old male with a malignant biliary stricture received 45 Gy external beam radiation in conjunction with 5-fluoruracil as a prelude to transplant. This was followed by a transluminal boost of radiation (2000 cGy) using an Iridium-192 brachytherapy wire inserted through percutaneously-placed biliary catheters. Using this approach, we document the complete resolution of the patient’s malignant stricture, thereby objectively quantifying tumor response prior to orthotopic liver transplantation.